Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993717 · ClinicalTrials.gov registry record
Solid Organ Transplant SHINGRIX
A clinical trial, sponsored by Emory University.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03993717: Clinical Trial study, sponsored by Emory University.
NCT03993717 is a clinical trial that was terminated before completion, run by Emory University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03993717 was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study will assess the immune responses to the recombinant, AS01-adjuvanted varicella zoster virus subunit (HZ/su) vaccine or SHINGRIX in immunosuppressed patients, particularly those who have received a renal transplant, and aim to better understand if the vaccine and perhaps other adjuvanted vaccines are safe in these patients. 30 participants will be divided into 2 groups, one group will receive the 1st out of 2 doses of the vaccine 3-6 months after transplant per standard of care and the second group will receive the 1st out of 2 doses of the vaccine 12-36 months after the transplant per standard of care.The duration of the study is 180 days.
Primary Outcome
Anti-gE antibody concentrations will be obtained via enzyme-linked immunosorbent assay (ELISA)
Interventions
- BIOLOGICAL SHINGRIX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-30 |
| Est. Completion | 2020-08-08 |
Why NCT03993717 stopped before completion
NCT03993717 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SHINGRIX is the first listed.
NCT03993717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03993717 about?
NCT03993717 is a clinical study titled "Solid Organ Transplant SHINGRIX". This study will assess the immune responses to the recombinant, AS01-adjuvanted varicella zoster virus subunit (HZ/su) vaccine or SHINGRIX in immunosuppressed patients, particularly those who have received a renal transplant, and aim to better understand if the vaccine and perhaps other adjuvanted v...
What is the current status of trial NCT03993717?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-01-30. Estimated completion is 2020-08-08.
What interventions are being tested in trial NCT03993717?
The interventions under investigation include: SHINGRIX (BIOLOGICAL).
Who is sponsoring clinical trial NCT03993717?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI